Formulation and evaluation of orodispersible tablet of ivabradine hydrochloride

D. B. Patel, K. J. Patel, P. D. Bharadia

Abstract


Objective: The objective of present research work was to develop formulation of orodispersible tablets of Ivabradine HCl and evaluate it for different evaluation parameters.

Methods: The tablets were prepared by direct compression method. The formulation of the tablets were evaluated before compression for characterization of flow properties and after compression for different parameters of orodispersible tablet formulation.

Results: Ivabradine hydrochloride orodispersible tablets were developed with considerable increase in drug release as compared to marketed formulations; nine formulations were developed and studied. The difference in drug release values was found to be 100.88 ± 0.10 respectively. The drug was characterized according to different compendial methods, on the basis of identification by HPLC, pH, organoleptic properties and other tests. Parameters evaluated were within prescribed limits and indicated good free flowing properties. The F6 batch with disintegration time 21 ± 3.0 and dissolution 99.29% was selected as optimized formulation. This was compared with conventional marketed formulation and was found superior. Batch F6 was also subjected to stability studies for two months and was tested for its hardness, wetting time, disintegration time, drug contents and dissolution behaviour monthly.

Conclusions: By appropriate selection of excipients, it was possible to develop orodispersible tablets of Ivabradine HCl.

Keywords


Orodispersible tablets, Ivabradine HCl, Superdisintegrants, Direct compression

Full Text:

PDF HTML XML

References


Anupam R. Orodispersible Tablets: A Review. Asian J Pharm Clin Res. 2016;9(1):19-26.

Debjit B, Chiranjib B, Krishna K, Chandira RM. Fast dissolving tablet: An overview. J Chem Pharm Res. 2009;1(1):163-77.

Sastry VS, Ram NJ, Joseph AF. Recent technological advances in oral drug delivery – A review. Pharm Sci Technolo Today. 2000;3(4):138-45.

Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst. 2004;21(6):433-76.

Doig C. Ivabradine: first of a new class of treatments for angina. Wily Online Library. 2009;17(15):14-7.

Tripathi KD. Essential of medical pharmacology; 6th edition. Jaypee brother’s medical publishers (P) Ltd. 2008: 521-538.

Maheshwari S, Khandhar AP. Quantitative Determination and Validation of Ivabradine HCl by Stability Indicating RP-HPLC Method and Spectrophotometric Method in solid Dosage Form. Eurasian J Anal Chem. 2010;5(1):53-62.

Kumar SP. Development and validation of stability indicating rapid HPLC method for estimation of Ivabradine Hydrochloride in solid dosage form. Int J Pharm Pharm Sci. 2014;6(4):378-82.

Afreen Q. Formulation and evaluation of Orodispersible tablets of Ivabradine by sublimation technique. Int J Pharm Analytical Res. 2015;4(4):478-90.

Swapna G. Formulation and in-vitro evaluation of Ivabradine Buccal Tablets. Int. J Trends Pharm Life Sci. 2015;1(4):457-70.

Sunitha S. Srinivasan BP. Development and validation of RP-HPLC method for the estimation of Ivabradine Hydrochloride in tablet. Indian J Pharm Sci. 2010;72(5):667-71.

Sagarika P. Rapid and Selective UV Spectrophotometric and RP-HPLC Methods for Dissolution Studies of Ivabradine Controlled Release Formulations. Pharma Tutor. 2014;2(8):210-3.

Patel KG. Development and validation of spectrofluorimetric method for estimation of Ivabradine hydrochloride in marketed formulation and its applicability in plasma. Der Pharmacia Lettre. 2014;6(5):8-13.

Damle MC. Development and validation of stability-indicating HPTLC method for Ivabradine HCl. Pharma Sci Monitor. 2015;6(1):141-52.

Fox K. Ivabradine – a selective and specific If inhibitor: efficacy and safety instable angina. European Heart J Suppl. 2003;5: G36-45.

Bekmetova FM. Efficacy of Ivabradine and bisoprolol based on the results of flow mediated dilation in patients with coronary heart disease. Int J Biomed. 2011;1(3):158-62.

Rahman R. Development and validation of RP-HPLC method for analysis of Ivabradine hydrochloride in tablet dosage forms. Res J Pharma Bio Chem Sci. 2012;3(3):1032.

Ramesh M, Mayur Vilas K, Dominique M, Ralph S, Jens G. Ivabradine-Containing Pharmaceutical Composition with Modified Release. United States US, US. 2011:20130116239A1.

Patrick W, Herve R, Marc J. Oral preparation of Ivabradine or the medical salt thereof. Espacenet, China (CN). 2008:CN101095682.

Lykoudis A, Grypioti A, Mandal JK. A solid pharmaceutical composition of Ivabradine for oral administration. WIPO (World Intellectual Property Organization), India. 2015:WO2015001569.

Kotar-Jordan B, Gojak U, Smrkolj M. Novel crystalline forms of Ivabradine hydrochloride. WIPO (World Intellectual Property Organization) & Espacenet (European patent), Berta (SI). 2011:WO2011098582.

Liang J, Feng X, Zhou Q, Yang Bo, Zhou J. Ivabradine hydrochloride osmotic pump controlled-release tablet and preparation method thereof. Espacenet (European patent), China. 2015:CN104398486.

Wagh MA, Kothawade P. Techniques used in orally disintegrating drug delivery system. Int J Drug Delivery. 2010;2(2):98-107.

Dhiraj A. Superdisintegrants: an emerging paradigm in orodispersible tablets. Int J Biopharmaceutics. 2013;(2):119-28.

Rowe R, Sheskey PJ, Quinn E. Handbook of pharmaceutical excipients, 6th edition. 2016: 115-581.




DOI: http://dx.doi.org/10.26510/2394-0859.pbe.2017.25

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2017 - Pharmaceutical and Biological Evaluations